Study at a glance
Can vitamin D affect hormone signals that help control blood pressure?
Renin starts a chain of hormone signals that can narrow blood vessels and affect fluid balance. Researchers tested whether vitamin D signals control this process in mice and cells. A separate trial asked whether vitamin D3 supplements lower blood pressure in older people. A change in one chain of processes in the body does not guarantee a change in blood pressure.
What did the mouse and cell experiments show about renin?
Mice without vitamin D receptors throughout the body had higher renin gene activity, higher angiotensin II, a hormone in this pathway, and higher blood pressure. A medicine that blocks the pathway removed the pressure difference in a small experiment. Renin stayed high after low calcium was corrected, although another hormone remained high. Active vitamin D reduced renin gene activity in mice and engineered mouse cells. Removing a receptor is not the same as having a modestly low vitamin D blood result.
Did vitamin D3 lower blood pressure in older people?
VitDISH assigned 159 people aged 70 or older with raised systolic pressure, the top blood-pressure number, to vitamin D3 or placebo. Treatment was given every three months for a year. Most already took blood-pressure medicines. Vitamin D blood levels rose, but the trial found no clear reduction in blood pressure or overall benefit in the vessel tests. The uncertainty allowed for some lowering or raising of pressure, rather than proving exactly no effect.
Do these findings establish vitamin D3 as a blood-pressure treatment?
The trial did not measure renin or angiotensin II, so it could not directly disprove the laboratory mechanism. It tested one treatment schedule in a selected older population and does not settle every age group or daily-dose approach. Exploratory differences between groups taking different medicines did not establish who benefits. The evidence does not establish vitamin D3 as a blood-pressure treatment or show fewer heart and circulation problems.
Read the full article below ↓Vitamin D signalling can reduce renin expression in mouse and cell experiments, but this does not establish that vitamin D supplements lower human blood pressure. A placebo-controlled trial in older people with isolated systolic hypertension found no clear pressure-lowering benefit from intermittent vitamin D3. The experimental and clinical findings answer different questions. For the detailed methods and appraisal, read Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full Study.
Why renin matters
Renin starts a hormone cascade that generates angiotensin II, which can narrow vessels and influence fluid balance. The kidneys provide this hormonal setting, while vascular tone describes one component of resistance to blood flow. Pressure depends on several interacting systems, so a change in one molecular pathway need not produce a predictable change in the whole circulation.
What the mouse experiments showed
Li and colleagues studied mice lacking vitamin D receptors throughout the body. Renal renin messenger RNA was more than threefold higher and circulating angiotensin II more than 2.5-fold higher than in wild-type mice. Systolic and diastolic pressures, measured under anaesthesia, were more than 20 mm Hg higher. The genotype difference was no longer apparent after a small captopril experiment, supporting involvement of the renin-angiotensin pathway.
Renin remained elevated in young mice before low calcium developed and after a mineral-rich diet corrected adult blood calcium. This argues against hypocalcaemia as the sole explanation. Parathyroid hormone (PTH) remained high, however, so its contribution in living animals was not fully excluded. Salt loading and water deprivation still changed renin in expected directions; receptor loss altered regulation without abolishing every feedback response.
Calcitriol, the active vitamin D hormone, reduced renal renin expression in wild-type mice. In engineered mouse kidney cells, receptor expression enabled strong suppression of renin and its promoter activity. These findings support a transcriptional mechanism. They do not establish a nutritional dose for humans, and global receptor deletion is a much larger biological change than a modestly low vitamin D blood result.
What VitDISH tested
VitDISH assigned 159 people aged at least 70 to cholecalciferol or placebo: 80 and 79 participants respectively. All were white and lived in one Scottish health-board area. Mean age was about 77, baseline office pressure approximately 163/78 mm Hg, and mean 25-hydroxyvitamin D 18 ng/mL. Participants took 100,000 IU every three months for one year, with masked treatment and concealed central allocation.
The prespecified primary comparison was office pressure at three months. Most participants already took antihypertensive medication. Vitamin D status rose and observed-dose adherence was high; 76 versus 74 attended three months, and 73 versus 69 attended twelve months. Raising the measured status marker therefore did not guarantee a corresponding functional response.
The result and its limits
The primary-results text reports a three-month systolic difference of −0.7 mm Hg, with a 95% confidence interval from −5.2 to 3.8. This includes both benefit and harm and provides no clear evidence of lowering pressure. Across follow-up, the systolic estimate was +1 mm Hg, with an interval from −2 to 4. Ambulatory pressure and the overall endothelial-dilation and arterial-stiffness measurements also showed no clear benefit.
An exploratory interaction with existing renin-angiotensin-blocking medicines does not establish a responsive subgroup. The trial did not measure renin or angiotensin II as reported outcomes, so it cannot directly refute the mouse mechanism. It also cannot settle every age group, daily-dose regimen or severe-deficiency setting. Supplementary methods and detailed adverse-event categories were unavailable for independent review; the main paper and registration support the conclusions presented here.
What this means
A receptor-dependent renin mechanism and a null supplementation result can both be valid. The evidence supports biological plausibility but does not establish vitamin D3 as a blood-pressure treatment or show fewer cardiovascular events. Interpreting the studies requires keeping the model, exposure and measured outcome together.
Scientific sources
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation. 2002;110(2):229-238. DOI: 10.1172/JCI15219. PMID: 12122115. Mouse and cell experiments; complete main paper, tables and figures examined.
Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.
University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.
Related reading
Influence of Vitamin D on the Incidence of Metabolic Syndrome and Hormonal Balance in Patients with Polycystic Ovary Syndrome
The majority of the patients with polycystic ovary syndrome were found to have deficient or suboptimal serum vitamin D levels, and the effects of vitamin D on the SHBG levels and free-androgen indices in these patients was examined.
Original paper ↗Read more →Klotho Deficiency Impairs Distal Potassium Homeostasis Through mTORC1‐Dependent Suppression of ROMK
In the present study, we aimed to determine whether Klotho deficiency impairs renal potassium handling and to examine the role of mTORC1 signaling in this process using KLhet mice.
Original paper ↗Read more →Quality of life and mental health in adolescent users of oral contraceptives. Results from the nationwide, representative German Health Interview and Examination Survey for Children and Adolescents (KiGGS)
Study participants had undergone standardized recordings of blood pressure and measurements of serum 25-hydroxyvitamin D [25(OH)D].
Original paper ↗Read more →The Role of Duration of Untreated Illness (DUI) on the Course and Biochemical Parameters of Female Patients Affected by Anorexia Nervosa
The purpose of the study was to investigate the role of duration of untreated illness (DUI) on the course and biochemical parameters in a sample of 76 female patients with AN.
Original paper ↗Read more →Vitamin D Enhances Efficacy of Oral Nifedipine in Treating Preeclampsia with Severe Features: A Double Blinded, Placebo-Controlled and Randomized Clinical Trial
We conduct a randomized trial of 683 primigravid women with preeclampsia, who were assigned to different treatment groups, either nifedipine+placebo or nifedipine+VD orally, by random after screening.
Original paper ↗Read more →Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full Study
Compare vitamin D receptor experiments in mice with the VitDISH blood-pressure trial, including renin mechanisms, human results and limits of translation.
Read more →Vitamin D Deficiency Aggravates Nephrotoxicity, Hypertension and Dyslipidemia Caused by Tenofovir: Role of Oxidative Stress and Renin-Angiotensin System
The aim of this study was to investigate the effects of VDD on TDF-induced nephrotoxicity.
Original paper ↗Read more →Dietary Calcium Intake and Hypertension: Importance of Serum Concentrations of 25-Hydroxyvitamin D
This population-based cross-sectional study examined the association between dietary calcium intake and hypertension and the influence of serum concentrations of 25-hydroxyvitamin D [25(OH)D] in Japanese subjects.
Original paper ↗Read more →Vitamin D and calcium status in pre-eclampsia and pregnancy-induced hypertension
In this observational cross-sectional study, 84 third-trimester women were enrolled from two hospitals in Lublin, Poland (41 PIH/PE, 43 controls).
Original paper ↗Read more →Salivary microbiome and hypertension in the Qatari population
Therefore, we examined the difference in the salivary microbiome composition between hypertensive and normotensive Qatari subjects.
Original paper ↗Read more →Arterial Structure and Function in Mild Primary Hyperparathyroidism Is Not Directly Related to Parathyroid Hormone, Calcium, or Vitamin D
We evaluated the possible vascular effects of these risk factors in patients with mild PHPT by using standard methods and new imaging techniques.
Original paper ↗Read more →Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with high arterial blood pressure and hypertension risk, but whether this association is causal is unknown.
Original paper ↗Read more →Efficacy of single-dose cholecalciferol in the blood pressure of patients with type 2 diabetes, hypertension and hypovitaminoses D
We investigated the effect of a single dose of 100,000 IU of cholecalciferol, in office blood pressure (BP), and 24-h ambulatory blood pressure monitoring (ABPM) in patients with type 2 diabetes mellitus (DM), hypertension, and hypovitaminosis D.
Original paper ↗Read more →Macrophage secretion of miR-106b-5p causes renin-dependent hypertension
Myeloid cells are known mediators of hypertension, but their role in initiating renin-induced hypertension has not been studied.
Original paper ↗Read more →Serum vitamin D, blood pressure and hypertension risk in the HUNT study using observational and Mendelian randomization approaches
We employed data from the Norwegian Trøndelag Health Study (HUNT) to conduct cross-sectional (n = 5854) and prospective (n = 3592) analyses, as well as one-sample MR (n = 86,324).
Original paper ↗Read more →Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway and Their Relationship with High Blood Pressure Risk
The aim of this study was to evaluate the effect of 13 single nucleotide polymorphisms (SNPs) related to the vitamin D metabolic pathway on the risk of developing HBP.
Original paper ↗Read more →The effect of daily UVA phototherapy for 2 weeks on clinic and 24-h blood pressure in individuals with mild hypertension
Latitude and season determine exposure to ultraviolet radiation and correlate with population blood pressure.
Original paper ↗Read more →Vitamin D Deficiency Induces High Blood Pressure and Accelerates Atherosclerosis in Mice
On a HF diet, vitamin D-deficient mice had ∼2-fold greater atherosclerosis in the aortic arch and ∼2 to 8-fold greater atherosclerosis in the thoracic and abdominal aorta compared to vitamin D-sufficient mice.
Original paper ↗Read more →Vitamin D Deficiency Is a Potential Risk for Blood Pressure Elevation and the Development of Hypertension
Background and objectives: Hypertension is a global health problem and a major risk factor for cardiovascular diseases.
Original paper ↗Read more →Vitamin D, Parathyroid Hormone and Their Associations with Hypertension in a Chinese Population
A population-based cross-sectional study was conducted among 1,420 Chinese participants, aged 20 to 83 years, in 2010.
Original paper ↗Read more →A randomized, double-blind, placebo-controlled trial of vitamin D supplementation with or without calcium in community-dwelling vitamin D deficient subjects
We aimed to assess whether vitamin D3 and calcium, either alone or in combination, have health benefit.
Original paper ↗Read more →Original sources
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Published in Journal of Clinical Investigation (2002).
Publication details
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation. 2002;110(2):229-238. DOI: 10.1172/JCI15219. PMID: 12122115. Mouse and cell experiments; complete main paper, tables and figures examined.
Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial
Published in JAMA Internal Medicine (2013).
Publication details
Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.
Vitamin D for Isolated Systolic Hypertension (VitDISH)
University of Dundee; study investigator Miles Witham.
Publication details
University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.